<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02400320</url>
  </required_header>
  <id_info>
    <org_study_id>202201</org_study_id>
    <nct_id>NCT02400320</nct_id>
  </id_info>
  <brief_title>Local Skin Safety Study of a Topical Pain Relief Spray Containing a Combination of Diclofenac, Methyl Salicylate, and Menthol</brief_title>
  <official_title>Cumulative Skin Irritation Study Evaluating the Skin Irritancy Potential of Topical Analgesic Vovilup Spray Containing a Combination of Diclofenac, Menthol, Methyl Salicylate and Linseed Oil and Comparing it With a Marketed Formulation - Iodex Ultragel</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine local skin safety of a topical analgesic spray&#xD;
      containing a combination of diclofenac, methyl salicylate, menthol and compare it with a&#xD;
      topical analgesic gel containing a combination of diclofenac, methyl salicylate, and menthol.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date type="Anticipated">March 1, 2016</start_date>
  <completion_date type="Anticipated">June 30, 2016</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean cumulative irritation score</measure>
    <time_frame>7 days</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Skin Irritation</condition>
  <arm_group>
    <arm_group_label>Topical Spray</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Topical spray containing Diclofenac 1.16%, Linseed Oil 3%, Menthol 5%, Methyl salicylate 10%.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Topical Gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topical gel containing Diclofenac 1.16%, Menthol 5%, Methyl salicylate 10%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topical Spray</intervention_name>
    <description>Topical spray containing Diclofenac 1.16%, Linseed Oil 3%, Menthol 5%, Methyl salicylate 10%.</description>
    <arm_group_label>Topical Spray</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topical Gel</intervention_name>
    <description>Topical gel containing Diclofenac 1.16%, Menthol 5%, Methyl salicylate 10%</description>
    <arm_group_label>Topical Gel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Saline</intervention_name>
    <description>Saline</description>
    <arm_group_label>Saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          1. Healthy male or female volunteers aged at least 18 years.&#xD;
&#xD;
          2. Good general, physical and mental health in the opinion of the investigator or&#xD;
             medically qualified designee:&#xD;
&#xD;
               -  No clinically significant and relevant abnormalities in medical history or upon&#xD;
                  physical examination.&#xD;
&#xD;
               -  Absence of any condition that could affect the volunteer's safety or well being&#xD;
                  or their ability to understand and follow study procedures and requirements.&#xD;
&#xD;
          3. Healthy volunteers who do not have excessive hair on the volar aspect of the&#xD;
             forearm(s).&#xD;
&#xD;
          4. Healthy volunteers should understand and be willing to fully comply with all study&#xD;
             procedures and restrictions.&#xD;
&#xD;
          5. Demonstrates understanding of the study and willingness to participate as evidenced by&#xD;
             voluntary written informed consent and has received a signed and dated copy of the&#xD;
             informed consent form.&#xD;
&#xD;
          6. Females of childbearing potential, using an effective contraceptive method for at&#xD;
             least one month before the beginning of the study, and willing to use throughout the&#xD;
             study&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Volunteers having recent history (within one year) of alcohol or other substance abuse&#xD;
             as determined by medical history.&#xD;
&#xD;
          2. Participation in another clinical study or receipt of an investigational drug within&#xD;
             30 days of the screening visit.&#xD;
&#xD;
          3. Previous participation in similar study with similar products.&#xD;
&#xD;
          4. Volunteer has any visible skin disease at the site of application that, in the opinion&#xD;
             of the investigator, will interfere with the skin assessments.&#xD;
&#xD;
          5. Volunteer has current or relevant previous history of serious, severe or unstable&#xD;
             physical or psychiatric illness, or medical disorders, such as current or previous&#xD;
             history of hepatic or renal diseases (impairment) or peptic ulcer as determined by&#xD;
             medical history.&#xD;
&#xD;
          6. Volunteer has a history of hypersensitivity (e.g. asthma, bronchospasm, rhinitis,&#xD;
             urticaria, nasal polyps) to aspirin, diclofenac, other non steroidal anti-inflammatory&#xD;
             drugs (NSAIDs), menthol or any of the excipients in the test product(s).&#xD;
&#xD;
          7. Volunteer is receiving systemic or topical NSAIDs, other oral or topical analgesics or&#xD;
             antihistamine within 3 days of visit 1, or other medication (such as corticosteroids&#xD;
             within 3 weeks of visit 1) which, in the opinion of the investigative personnel, will&#xD;
             interfere with the study results.&#xD;
&#xD;
          8. Female volunteers who are pregnant, planning to become pregnant during the study, or&#xD;
             are breast-feeding.&#xD;
&#xD;
          9. Female volunteers who have positive pregnancy test.&#xD;
&#xD;
         10. Volunteers who are employees of the sponsor or study site or an immediate family&#xD;
             member (e.g. partner, offspring, parents, siblings or sibling's offspring) of such&#xD;
             employees.&#xD;
&#xD;
         11. Any skin disorder at the test site that in the investigator's judgement can affect the&#xD;
             readings of the test result&#xD;
&#xD;
         12. Any concomitant medications that in the investigator's judgement can confound or alter&#xD;
             test results or evaluation of adverse events.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <verification_date>September 2017</verification_date>
  <study_first_submitted>January 29, 2015</study_first_submitted>
  <study_first_submitted_qc>March 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2015</study_first_posted>
  <last_update_submitted>September 11, 2017</last_update_submitted>
  <last_update_submitted_qc>September 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

